The Motley Fool5d
Vertex Pharma Just Scored a Major FDA Approval. Is the Stock a No-Brainer Buy Now?
Vertex just won approval for a drug to treat one of the most common health problems -- pain. The biotech company is offering an option for patients and doctors who don’t want to go for ...
Vertex Pharmaceuticals price target raised to $540 from $522 at BofA
BofA analyst Tazeen Ahmad raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $540 from $522 and keeps a Buy rating on the ...
Vertex Pharmaceuticals (VRTX) Gets a Buy from J.P. Morgan
In a report released yesterday, Jessica Fye from J.P. Morgan maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with a ...
STAT6d
The first shot taken at Medicaid, and Optum’s wellness visit ad
UnitedHealthcare likely to cover Vertex’s pain drug Vertex Pharmaceuticals received FDA approval for a new non-opioid pain drug, marketed as Journavx, and it appears the nation’s largest ...
pharmaphorum2d
Vertex gets EU okay to treat younger cystic fibrosis patients
A new EMA approval has expanded the use of Vertex Pharma’s cystic fibrosis therapy Symkevi to children as young as six if they have specific gene mutations. The regulator has given a green light ...
pharmaphorum1d
Vertex buys diabetes cell therapy rival ViaCyte for $320m
Vertex' therapy takes the form of stem cell-derived human pancreatic islet cells, which secrete insulin in the body in response to rising blood glucose. The aim is to replace the pancreatic tissue ...
Yahoo Finance5d
Vertex Pharmaceuticals Incorporated (VRTX)
Get prepared with the key expectations. Vertex Pharmaceuticals (NASDAQ: VRTX) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs, and this platform has helped ...
Zacks.com on MSN3d
Unlocking Q4 Potential of Vertex (VRTX): Exploring Wall Street Estimates for Key Metrics
The upcoming report from Vertex Pharmaceuticals (VRTX) is expected to reveal quarterly earnings of $3.99 per share, indicating a decline of 5% compared to the year-ago period. Analysts forecast ...
Reuters4d
Formula 1
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...
FIA Formula E2d
Your Guide to Formula E
Leveraging a roster of innovative technical upgrades, the GEN3 Evo unveiled at H.S.H Prince Albert II’s Private Car Collection will debut in Season 11 of the ABB FIA Formula E World Championship.
FIA Formula E12h
Cars and tech subheading
Formula E is set to get a lot faster with the introduction of the GEN3 Evo, the quickest accelerating FIA single-seater race car – Capable of 0-60mph in 1.82 seconds (0-100kph in 1.86s). Set to race ...